Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8.

@article{Curfman2005ExpressionOC,
  title={Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8.},
  author={Gregory D. Curfman and Stephen Morrissey and Jeffrey M Drazen},
  journal={The New England journal of medicine},
  year={2005},
  volume={353 26},
  pages={2813-4}
}
We have recently obtained information regarding inaccuracies in data in the report of the VIGOR (Vioxx Gastrointestinal Outcomes Research) study by Bombardier et al.1 that raise concern about certain conclusions in the article. The VIGOR study was designed primarily to compare gastrointestinal events in patients with rheumatoid arthritis randomly assigned to treat­ ment with rofecoxib (Vioxx) or naproxen (Napro­ syn), but data on cardiovascular events were also monitored. Three myocardial… CONTINUE READING
60 Citations
1 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 60 extracted citations

Similar Papers

Loading similar papers…